125 related articles for article (PubMed ID: 26434819)
21. Aberrant methylation of the PTPRO gene in peripheral blood as a potential biomarker in esophageal squamous cell carcinoma patients.
You YJ; Chen YP; Zheng XX; Meltzer SJ; Zhang H
Cancer Lett; 2012 Feb; 315(2):138-44. PubMed ID: 22099875
[TBL] [Abstract][Full Text] [Related]
22. Aberrant PTPRO methylation in tumor tissues as a potential biomarker that predicts clinical outcomes in breast cancer patients.
Li SY; Li R; Chen YL; Xiong LK; Wang HL; Rong L; Luo RC
BMC Genet; 2014 Jun; 15():67. PubMed ID: 24919593
[TBL] [Abstract][Full Text] [Related]
23. Protein tyrosine phosphatase receptor type O regulates development and function of the sensory nervous system.
Gonzalez-Brito MR; Bixby JL
Mol Cell Neurosci; 2009 Dec; 42(4):458-65. PubMed ID: 19800005
[TBL] [Abstract][Full Text] [Related]
24. Blockage of PTPRJ promotes cell growth and resistance to 5-FU through activation of JAK1/STAT3 in the cervical carcinoma cell line C33A.
Yan CM; Zhao YL; Cai HY; Miao GY; Ma W
Oncol Rep; 2015 Apr; 33(4):1737-44. PubMed ID: 25634668
[TBL] [Abstract][Full Text] [Related]
25. The roles of protein tyrosine phosphatases in bone-resorbing osteoclasts.
Shalev M; Elson A
Biochim Biophys Acta Mol Cell Res; 2019 Jan; 1866(1):114-123. PubMed ID: 30026076
[TBL] [Abstract][Full Text] [Related]
26. Protein tyrosine phosphatase receptor type O expression in the tumor niche correlates with reduced tumor growth, angiogenesis, circulating tumor cells and metastasis of breast cancer.
Liu Z; Hou J; Ren L; He J; Sun B; Sun LZ; Wang S
Oncol Rep; 2015 Apr; 33(4):1908-14. PubMed ID: 25646811
[TBL] [Abstract][Full Text] [Related]
27. PTPRO-mediated autophagy prevents hepatosteatosis and tumorigenesis.
Zhang W; Hou J; Wang X; Jiang R; Yin Y; Ji J; Deng L; Huang X; Wang K; Sun B
Oncotarget; 2015 Apr; 6(11):9420-33. PubMed ID: 25826083
[TBL] [Abstract][Full Text] [Related]
28. PTPRO Promotes Oxidized Low-Density Lipoprotein Induced Oxidative Stress and Cell Apoptosis through Toll-Like Receptor 4/Nuclear Factor κB Pathway.
Liang C; Wang X; Hu J; Lian X; Zhu T; Zhang H; Gu N; Li J
Cell Physiol Biochem; 2017; 42(2):495-505. PubMed ID: 28578349
[TBL] [Abstract][Full Text] [Related]
29. Protein tyrosine phosphatases in osteoclast differentiation, adhesion, and bone resorption.
Granot-Attas S; Elson A
Eur J Cell Biol; 2008 Sep; 87(8-9):479-90. PubMed ID: 18342392
[TBL] [Abstract][Full Text] [Related]
30. PTPRO is a therapeutic target and correlated with immune infiltrates in pancreatic cancer.
Hou X; Du J; Fang H
J Cancer; 2021; 12(24):7445-7453. PubMed ID: 35003364
[TBL] [Abstract][Full Text] [Related]
31. Antibodies to protein tyrosine phosphatase receptor type O (PTPro) increase glomerular albumin permeability (P(alb)).
Charba DS; Wiggins RC; Goyal M; Wharram BL; Wiggins JE; McCarthy ET; Sharma R; Sharma M; Savin VJ
Am J Physiol Renal Physiol; 2009 Jul; 297(1):F138-44. PubMed ID: 19403647
[TBL] [Abstract][Full Text] [Related]
32. Methylation and silencing of protein tyrosine phosphatase receptor type O in chronic lymphocytic leukemia.
Motiwala T; Majumder S; Kutay H; Smith DS; Neuberg DS; Lucas DM; Byrd JC; Grever M; Jacob ST
Clin Cancer Res; 2007 Jun; 13(11):3174-81. PubMed ID: 17545520
[TBL] [Abstract][Full Text] [Related]
33. The tyrosine phosphatase PTPRD is a tumor suppressor that is frequently inactivated and mutated in glioblastoma and other human cancers.
Veeriah S; Brennan C; Meng S; Singh B; Fagin JA; Solit DB; Paty PB; Rohle D; Vivanco I; Chmielecki J; Pao W; Ladanyi M; Gerald WL; Liau L; Cloughesy TC; Mischel PS; Sander C; Taylor B; Schultz N; Major J; Heguy A; Fang F; Mellinghoff IK; Chan TA
Proc Natl Acad Sci U S A; 2009 Jun; 106(23):9435-40. PubMed ID: 19478061
[TBL] [Abstract][Full Text] [Related]
34. Expression Analysis of Tyrosine Phosphatase Genes at Different Stages of Renal Cell Carcinoma.
Laczmanska I; Laczmanski L; Sasiadek MM
Anticancer Res; 2020 Oct; 40(10):5667-5671. PubMed ID: 32988891
[TBL] [Abstract][Full Text] [Related]
35. Survival and inflammation promotion effect of PTPRO in fulminant hepatitis is associated with NF-κB activation.
Jiang R; Chen D; Hou J; Tan Z; Wang Y; Huang X; Wang X; Sun B
J Immunol; 2014 Nov; 193(10):5161-70. PubMed ID: 25339662
[TBL] [Abstract][Full Text] [Related]
36. Targeting Receptor-Type Protein Tyrosine Phosphatases with Biotherapeutics: Is Outside-in Better than Inside-Out?
Senis YA; Barr AJ
Molecules; 2018 Mar; 23(3):. PubMed ID: 29498714
[TBL] [Abstract][Full Text] [Related]
37. Tyrosine Phosphatase PTPRO Deficiency in ERBB2-Positive Breast Cancer Contributes to Poor Prognosis and Lapatinib Resistance.
Dong H; Du L; Cai S; Lin W; Chen C; Still M; Yao Z; Coppes RP; Pan Y; Zhang D; Gao S; Zhang H
Front Pharmacol; 2022; 13():838171. PubMed ID: 35431974
[TBL] [Abstract][Full Text] [Related]
38. Protein Tyrosine Phosphatase PTPRO Signaling Couples Metabolic States to Control the Development of Granulocyte Progenitor Cells.
Li Y; Jia A; Yang H; Wang Y; Wang Y; Yang Q; Cao Y; Bi Y; Liu G
J Immunol; 2022 Mar; 208(6):1434-1444. PubMed ID: 35246496
[TBL] [Abstract][Full Text] [Related]
39. Transforming growth factor {beta} (TGF-{beta})-Smad target gene protein tyrosine phosphatase receptor type kappa is required for TGF-{beta} function.
Wang SE; Wu FY; Shin I; Qu S; Arteaga CL
Mol Cell Biol; 2005 Jun; 25(11):4703-15. PubMed ID: 15899872
[TBL] [Abstract][Full Text] [Related]
40. PTPROt maintains T cell immunity in the microenvironment of hepatocellular carcinoma.
Hou J; Deng L; Zhuo H; Lin Z; Chen Y; Jiang R; Chen D; Zhang X; Huang X; Sun B
J Mol Cell Biol; 2015 Aug; 7(4):338-50. PubMed ID: 26117839
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
